Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report

References

• LeeJYNooSMChoNHA rare case of primary adenosquamous carcinoma arising from ovaryJ Women’s Med20103126129
   Google Scholar
• MorganRJJrArmstrongDKAlvarezRDOvarian cancer, version 1.2016: clinical practice guidelines in oncologyJ Natl Compr Canc Netw20161491134116327587625
   PubMed Web of Science ®Google Scholar
• BookmanMAStandard treatment in advanced ovarian cancer in 2005: the state of the artInt J Gynecol Cancer200515Suppl 321222016343233
   PubMed Web of Science ®Google Scholar
• OronskyBRayCMSpiraAITrepelJBCarterCACottrillHMA brief review of the management of platinum-resistant–platinum-refractory ovarian cancerMed Oncol201734610310928444622
   PubMed Web of Science ®Google Scholar
• ZhangSRoyerRLiSFrequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancerGynecol Oncol2011121235335721324516
   PubMed Web of Science ®Google Scholar
• JaysonGCKohnECKitchenerHCLedermannJAOvarian cancerLancet201438499511376138824767708
   PubMed Web of Science ®Google Scholar
• SayalKGounarisIBasuBEpirubicin, cisplatin, and capecitabine for primary platinum-resistant or platinum-refractory epithelial ovarian cancer: results of a retrospective, single-institution studyInt J Gynecol Cancer201525697798425962114
   PubMed Web of Science ®Google Scholar
• YuCQYuJHanJZhouQLShenWRegulatory mechanism of malignant behavior of endometriosis mediated by puerarinJ Chin Integr Med2009714347 Chinese
   Google Scholar
• ShojiTTakatoriEMurakamiKA case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic reviewJ Ovarian Res201691485427514842
   PubMed Web of Science ®Google Scholar
• XuLZhouQLHanJEffects of Chinese herbal medicine Neiyi Recipe-medicated serum on angiopoiesis of endometriosis in the chick chorioallantoic membrane modelJ Chin Integr Med2012107800806
   Google Scholar
• McClungECWenhamRMProfile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesInt J Womens Health20168597527051317
   PubMedGoogle Scholar
• ZhangMTianZSunYSuccessful treatment of ovarian cancer with apatinib combined with chemotherapyMedicine (United States)201796454549
   Google Scholar
• DengLWangYLuWLiuQWuJJinJApatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case reportOnco Targets Ther2017101521152528352185
   PubMed Web of Science ®Google Scholar
• du BoisAFloquetAKimJWIncorporation of pazopanib in maintenance therapy of ovarian cancerJ Clin Oncol201432303374338225225436
   PubMed Web of Science ®Google Scholar
• El HelaliAMcCabeNDicksonNAcquired platinum resistance enhances tumour angiogenesis through activation of vascular mimicryCancer Res20177713152158
   Google Scholar
• KimGIsonGMcKeeAEFDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapyClin Cancer Res201521194257426126187614
   PubMed Web of Science ®Google Scholar
• McLachlanJBanerjeeSOlaparib for the treatment of epithelial ovarian cancerExpert Opin Pharmacother2016177995100326967466
   PubMed Web of Science ®Google Scholar
• HazarikaMChukMKTheoretMRU.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumabClin Cancer Res201723143484348828087644
   PubMed Web of Science ®Google Scholar
• BaroneAHazarikaMTheoretMRFDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanomaClin Cancer Res201723195661566528179454
   PubMed Web of Science ®Google Scholar
• Pai-ScherfLBlumenthalGMLiHFDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyondOncologist201722111392139928835513
   PubMed Web of Science ®Google Scholar
• VargaAPiha-PaulSAOttPAPembrolizumab in patients (pts) with PD-L1-positive (PD-L1+) advanced ovarian cancer: updated analysis of KEYNOTE-028J Clin Oncol201735155513
   Web of Science ®Google Scholar
• WenhamRMDormanDLeeJKApteSMShahzadMMChonHSPhase 2 trial of dose dense (weekly) paclitaxel with pembrolizumab in platinum resistant recurrent ovarian cancerInt J Gynecol Cancer201626877881
   Web of Science ®Google Scholar
• MatulonisUAChenMPuhlmannMShentuYLedermannJKEYNOTE-100: phase 2 trial of pembrolizumab in patients with advanced recurrent ovarian cancerAnn Oncol201627Suppl 6296312
   Google Scholar
• HamanishiJMandaiMIkedaTSafety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancerJ Clin Oncol201533344015402226351349
   PubMed Web of Science ®Google Scholar
• SunLMLiuYCLiWNivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expressionEur Rev Med Pharmacol Sci20172161198120528387913
   PubMed Web of Science ®Google Scholar
• PrasadVKaestnerVNivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeableSemin Oncol201744213213528923211
   PubMed Web of Science ®Google Scholar
• ZhuXLangJProgrammed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancerJ Gynecol Oncol2017285e6428657225
   PubMed Web of Science ®Google Scholar
• GuanXWangHMaFQianHYiZXuBThe efficacy and safety of programmed cell death 1 and programmed cell death 1 ligand inhibitors for advanced melanoma: a meta-analysis of clinical trials following the PRISMA guidelinesMedicine (United States)20169511e3134
   Google Scholar
• StricklandKCHowittBEShuklaSAAssociation and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancerOncotarget2016712135871359826871470
   PubMedGoogle Scholar
• JiaoSXiaWYamaguchiHPARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppressionClin Cancer Res201723143711372028167507
   PubMed Web of Science ®Google Scholar
• LimJSJTanDSPUnderstanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitorsCancers201798109123
   PubMed Web of Science ®Google Scholar